Additionally, the rates of achieving a weekly average reduction of ≥ 4 points from baseline in the daily PP-NRS score were 67.3% and 60.5%, respectively. Long-term treatment with Stapokibart can ...

March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate ...

Three new drug applications of Stapokibart for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, chronic rhinosinusitis with nasal polyposis (CRSwNP) and seasonal allergic rhinitis ...

Three new drug applications of Stapokibart for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, chronic rhinosinusitis with nasal polyposis (CRSwNP) and seasonal allergic ...

the drug achieved a significant and "clinically meaningful" reduction in the Pain Intensity Numeric Rating Scale (PI-NRS) less than two weeks after starting treatment At the end of study – which ...

Sativex, developed by GW Pharmaceuticals and marketed in the UK by Bayer, has been shown to provide significant improvement in the 0-10 numeric rating scale (NRS) spasticity score and spasm ...

We use cookies to authenticate, authorize, verify, analyze and secure the application. The application will not work with cookies disabled. if the cookies are ...